Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPA

This article was originally published in The Tan Sheet

Executive Summary

Hemorrhagic stroke risk is due to abuse of PPA-containing weight loss drugs, not proper use of cough/cold remedies, Michael Ernst and Arthur Hartz, MD/PhD, University of Iowa and William Wolowich, Children's Hospital, Columbus, Ohio, et al., state in letters in April 5 New England Journal of Medicine. "Patients who take [PPA] as a weight-loss aid commonly abuse the drug by taking it in higher-than-recommended doses," Wolowich notes. HSP authors Walter Kernan et al. respond their data showed stroke risk also was linked to proper use of cough/cold OTCs, but acknowledge weight loss doses were higher. NEJM released the HSP's findings last November (1"The Tan Sheet" Nov. 13, 2000, p. 4)
Advertisement

Related Content

Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.
Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.

Topics

Advertisement
UsernamePublicRestriction

Register

PS092409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel